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Empiric antibiotic treatmentThe impact of the short-incubation matrix-assisted laser desorption ionization time-of-ﬂight (si-MALDI-TOF)
mass spectrometry technique was evaluated in the treatment of bloodstream infections (BSIs) caused by
Pseudomonas aeruginosa, Enterococcus spp., and Amp-C producing Enterobacteriaceae. A total of 124 bacteremia
episodes were divided into 2 groups: i) si-MALDI-TOF group (n=69) and ii) control group (n=55). Identiﬁca-
tion by si-MALDI-TOF resulted in 12.8% increase in cases receiving appropriate antibiotic treatment within 48 h
from blood culture draw. The importance of the rapid identiﬁcation was emphasized in BSIs caused by entero-
cocci (n = 62), where si-MALDI-TOF led to appropriate antibiotic treatment in 87.9% of cases (versus control
group 65.5%, P=0.036). Implementation of si-MALDI-TOF technology formicrobial identiﬁcationwas associated
with increased proportion of patients receiving effective antibiotic treatment within 48 h from blood culture
draw. The effect was most signiﬁcant in BSIs caused by enterococcal species and in a subgroup of immunosup-
pressed patients..
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The cornerstone of the management of bloodstream infections
(BSIs) is rapid identiﬁcation of the causative organism (Seifert, 2009).
This will enable timely and appropriate antibiotic treatment, which is
the most important predictor of a better outcome in patients with BSI
(Ibrahim et al., 2000; Leibovici et al., 1998). This issue is relevant be-
cause BSIs cause a signiﬁcant burden of disease with an increasing inci-
dence (Skogberg et al., 2012).
Matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-
TOF)mass spectrometry has changed the ﬁeld of rapidmicrobial identi-
ﬁcation in clinical microbiology, especially in bacteremias (Drancourt,
2010). This technique allows a shorter time from blood culture draw
to organism identiﬁcation in patients with BSI compared with tradi-
tional methods (Bizzini and Greub, 2010; Martiny et al., 2013). Several
studies have shown this technique's beneﬁt on antibiotic treatment in
patients with BSI (Clerc et al., 2013; Huang et al., 2013; Vlek et al.,
2012). Combined with antimicrobial stewardship team intervention, it
has been associated with reduced mortality and shorter hospital stay
in patients with BSI (Huang et al., 2013). In addition, combinedwith an-
timicrobial stewardship team intervention, it has been shown to be
cost-effective (Patel et al., 2016; Perez et al., 2013). MALDI-TOF analysiscombined with a short subculture time of positive blood cultures (si-
MALDI-TOF) is an improvement of this technique, allowing even shorter
time to pathogen identiﬁcation with a positive effect on antibiotic ther-
apy (Idelevich et al., 2014; Kohlmann et al., 2015), and is also associated
with reduced length of hospital stay and mortality in patients with BSI
(Delport et al., 2017).
In BSIs caused by Pseudomonas aeruginosa, Enterococcus spp., and
AmpC-producing Enterobacteriaceae, empiric antibiotic therapy is
likely to be inappropriate due to their natural resistance proﬁle. This
stresses the need for a faster recognition of these pathogens in blood-
stream, especially since the beneﬁt of timely and appropriate antibiotic
treatment has been demonstrated also with these pathogens (Huang
et al., 2013; Kang et al., 2003; Zasowski et al., 2016). An increase inmor-
tality was observed in patients with delay in receiving appropriate anti-
biotic therapy over 48 h from blood culture draw (Lodise et al., 2007;
Zasowski et al., 2016). Previous studies have also suggested particular
beneﬁt of MALDI-TOF in bacteremias caused by these pathogens
(Clerc et al., 2013; Osthoff et al., 2016). However, in most studies, the
impact of MALDI-TOF analysis is evaluated in combinationwith antimi-
crobial stewardship team and/or infectious disease (ID) consultation.
In the present study, we investigate the impact of si-MALDI-TOF on
antibiotic treatment of BSIs caused by Pseudomonas aeruginosa, Entero-
coccus spp., and AmpC-producing Enterobacteriaceae.We hypothesized
that si-MALDI-TOF would enable patients to receive appropriate antibi-
otic treatment faster. Time from blood culture draw to the receipt ofubationMALDI-TOFMS on empiric antibiotic therapy
s://doi.org/10.1016/j.diagmicrobio.2018.11.009
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ﬁts of si-MALDI-TOF (Timbrook et al., 2017). Therefore, the primary out-
come of the study was the percentage of patients receiving appropriate
antibiotic therapy within 48 h after the blood culture draw.2. Materials and methods
2.1. Patients and study design
This was a retrospective, observational study of adult patients with
BSIs caused by Pseudomonas aeruginosa, Enterococcus spp., and AmpC-
producing Enterobacteriaceae (including Enterobacter spp., Serratia
spp., and Morganella morganii) between March 2014 and December
2015 at Helsinki University Hospital (HUH). Patients were identiﬁed
from the clinical microbiology laboratory database at Helsinki Univer-
sity Hospital Laboratory (HUSLAB). Only the ﬁrst BSI episode of patients
withmultiple episodes of the samebacteria during the study periodwas
included.
HUH is a tertiary hospital serving population about one and a half
million in the Hospital District of Helsinki and Uusimaa. The prevalence
of multidrug-resistant Pseudomonas aeruginosa is low (65 cases year
2015). Also, the prevalence of vancomycin-resistant enterococci (VRE)
is low (under 20 cases annually past few years). The research board of
the Inﬂammation Center at the Helsinki University Hospital approved
the study protocol.Table 1
Patient characteristics and focus or source of infection.
Whole study
group
(n = 124)
Si-MALDI-TOF
Group
(n = 69)
Control
group
(n = 55)
P
value
Patient characteristics
Age, years (mean; SD) 61.3; 15.2 62.7; 15.6 59.6; 14.7 0.257
Gender, male; n (%) 74 (59.7) 42 (60.9) 32 (58.2) 0.762
Chronic heart disease 14 (11.3) 9 (13.0) 5 (9.1) 0.490
Chronic kidney disease 22 (17.7) 11 (15.9) 11 (20.0) 0.557
Dialysis 4 (3.2) 2 (2.9) 2 (3.6) N0.99
Liver cirrhosis 5 (4.0) 4 (5.8) 1 (1.8) 0.381
Chronic lung disease 18 (14.5) 11 (15.9) 7 (12.7) 0.614
Diabetes 26 (21.0) 14 (20.3) 12 (21.8) 0.835
Blood malignancya 14 (11.3) 10 (14.5) 4 (7.3) 0.207
Acute leukemia 15 (12.1) 9 (13.0) 6 (10.9) 0.717
Stem cell transplant 5 (4.0) 2 (2.9) 3 (5.5) 0.654
Solid organ malignancy 32 (25.8) 16 (23.2) 16 (29.1) 0.4562.2. Identiﬁcation of bacteria
The si-MALDI-TOF identiﬁcation was done from all blood culture
bottles (BacT/Alert FA Plus, FN/PF Plus, FA, SN, and PF; bioMérieux)
which ﬂagged positive between 8 p.m. and 11 a.m. (si-MALDI-TOF
group). For the analysis, 50–100 μl of blood culture content was applied
on chocolate agar plates, which were incubated for 3–4 h at +35 °C in
CO2. After incubation, a sample for the MALDI-TOF analysis was taken
by streaking the application area on the chocolate agar. One spotwas in-
oculated for each sample. The analysis (VitekMS; bioMérioux) was per-
formed even if no growth was visible. Simultaneously with the si-
MALDI-TOF analysis, another sample from blood culture bottle was
Gram stained and subcultured on agar plates for susceptibility and iden-
tiﬁcation conﬁrmatory testing. Additionally, a sample from a positive
blood culture bottle was used for conventional bacterial identiﬁcation
(in-house identiﬁcation set containing 10 biochemical tests, as well as
chromogenic plates). On the next day, a conventional MALDI-TOF was
performed in cases giving unreliable identiﬁcation in conventional bio-
chemical analysis. The si-MALDI-TOF results were reported between
11 a.m. and 2 p.m., and the results for the control group were reported
on the next day between 9 a.m. and 11 a.m. As a consequence, identiﬁ-
cation by si-MALDI-TOF resulted in initial identiﬁcation roughly 22–
24 h earlier than the one achieved by conventional MALDI-TOF and bio-
chemical identiﬁcation methods.Solid organ transplant 18 (14.5) 10 (14.5) 8 (14.5) 0.993
Immunosuppressive
treatmentb
70 (56.5) 44 (63.8) 26 (47.3) 0.066
Neutropeniac 21 (16.9) 14 (20.3) 7 (12.7) 0.265
Infection focus or source
Pulmonary 5 (4.0) 2 (2.9) 3 (5.5) 0.654
Urinary tract 21 (16.9) 13 (18.8) 8 (14.5) 0.526
Skin/musculoskeletal 7 (5.6) 5 (7.2) 2 (3.6) 0.461
Abdominal cavity 55 (44.4) 28 (40.6) 27 (49.1) 0.343
Central nervous system 1 (0.8) 1 (1.4) 0 N0.99
Heart 2 (1.6) 1 (1.4) 1 (1.8) N0.99
Indwelling catheter 5 (4.0) 1 (1.4) 4 (7.3) 0.170
Unknown 28 (22.6) 18 (26.1) 10 (18.2) 0.296
a Other than acute leukemia.
b Antirejection medication, cancer chemotherapy, prednisolone more than 10 mg/day,
and antirheumatic medications including biological medications.
c Absolute neutrophil cell count less than 0.5 × 105 neutrophils/mL.2.3. Data collection and statistics
An infectious disease specialist (M.H.) reviewed medical records
of each patient. Demographic and clinical data were collected.
Demographic data were analyzed using descriptive statistics. Categori-
cal variables were analyzed using Chi-square analysis or Fisher's exact
test when appropriate. Mann–Whitney U test was used in continuous
variables if data were not normally distributed; otherwise, a 2-tailed
Student t test was used. Kaplan–Meier method and log-rank test were
used to analyze survival (type) data. P value b0.05 was considered sta-
tistically signiﬁcant. Statistical analyses were performed using SPSS
software, version 22.0 (SPSS, Inc., Chicago, IL).Please cite this article as:M. Halavaara, A. Nevalainen, T. Martelius, et al., Im
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Index bacteria mean one of the bacteria that are included in the
study. Index bacteria are Pseudomonas aeruginosa, Enterococcus spp.,
and AmpC-producing Enterobacteriaceae (Enterobacter spp., Serratia
spp., andMorganella morganii). Polymicrobial bacteremia was deﬁned
as the isolation of more than 1 bacterial species during the same bacter-
emia episode, except when the second microorganism was considered
to be a contaminant. The focus or source of BSI was assessed on the
basis of medical records.
Immunosuppressive treatment included antirejection medication,
cancer chemotherapy, prednisolone more than 10 mg/day, and anti-
rheumatic medications including biological medications (Table 1). Pa-
tients in this group are similar in a way that they all receive or have
received immunosuppressive medication and are in a close follow-up
of appropriate specialty. So, in their case, immunosuppression is clearly
deﬁned and is due to medication and comorbidity also. Patients with a
disease associated with varying degree of immunosuppression (e.g., di-
abetes or liver disease) are a more heterogeneous group and harder to
deﬁne. Thus, patients with these comorbidities are not included in the
subgroup analysis including immunosuppressed patients.
2.5. Study deﬁnitions about antibiotic therapy
Appropriate antibiotic therapy was deﬁned as an antibiotic regimen
(i) to which the index bacteriumwas susceptible in vitro, (ii) considered
standard treatment according to Helsinki University Hospital's antimicro-
bial treatment guide, and (iii) delivered intravenously (with the excep-
tion of ﬂuoroquinolones). For example, antipseudomonal beta-lactam or
ﬂuoroquinolone for Pseudomonas aeruginosa BSI was considered
appropriate, while monotherapy with aminoglycosides was inappropri-
ate. Similarly, ﬁrst-, second-, and third-generation cephalosporins and
monotherapy with aminoglycosides were considered inappropriate for
AmpC-producing Enterobacteriaceae. Time to the appropriate antibioticpact of short-incubationMALDI-TOFMS on empiric antibiotic therapy
ious Disease, https://doi.org/10.1016/j.diagmicrobio.2018.11.009
Table 2
Number of bacteremic episodes according to the causative bacteria (n = 124).
All
episodes
Si-MALDI-TOF
group
Control
group
P
value
Pseudomonas
aeruginosa
21 14 7 0.265
Enterococcus spp. 62 33 29 0.588
E. faecalis 22 11 11
E. faecium 37 21 16
E casseliﬂavum 3 1 2
AmpC-producing
Enterobacteriaceae
41 22 19 0.754
E. aerogenes 2 1 1
E. cloacae 21 11 10
Serratia liquefaciens 1 1 0
Serratia marcescens 13 6 7
Morganella morganii 4 3 1
3M. Halavaara et al. / Diagnostic Microbiology and Infectious Disease xxx (xxxx) xxxtherapy was calculated from the time of the ﬁrst positive blood culture
draw to the delivery of ﬁrst dose of appropriate antibiotic.
2.6. Exclusion criteria
Patient exclusion criteria were i) transfer to another hospital before
receipt of appropriate antibiotic therapy or lack of veriﬁed clinical de-
tails (data could not be obtained) (n = 25), ii) patient did not receive
appropriate antibiotic treatment at all by the decision of the treating
physician (e.g., due to poor prognosis) (n=6), iii) bacteremia episodes
during the appropriate antibiotic treatment (n= 5), and iv) blood cul-
ture result ruled as a contamination by the treating physician (n=4; in
these cases, blood culture was drawn through a catheter and did not
correlate with clinical situation).
3. Results
3.1. General
A total of 164 episodes of bacteremia caused by the index bacteria
were identiﬁed. According to exclusion criteria, 40 episodes were ex-
cluded (as shown in more detail is Subsection 2.6.), and resulting 124
bacteremia episodes originating from 120 patients were included in
the study. One patient had 2 separate bacteremias of different index
bacteria during the study period. Three patients had a polymicrobial
bacteremia caused by 2 of the index bacteria. Consequently, both
these ﬁndings were analyzed as separate episodes. The number of
polymicrobial bacteremias including only 1 of index bacteria was 15.
One hundred twenty-four bacteremia episodes were divided into 2
groups: i) si-MALDI-TOF group (n = 69), i.e., si-MALDI-TOF was used
for bacterial identiﬁcation with a positive result, and ii) control group
(n = 55), i.e., identiﬁcation was done by means of conventional
methods (including those cases where si-MALDI-TOF was done but
was negative). For more details, see Subsection 2.2.
The site of acquisition of the blood culture was emergency room in
33.9% (n=42), intensive care unit in 12.9% (16), internal medicine (in-
cluding pulmonology and neurology) ward in 4.8% (6), hematology
ward in 13.7% (17), surgical ward in 25.8% (32), gynecology ward in
3.2% (4), and oncology ward in 5.6% (7) of cases.
Baseline demographic characteristics were similar in both study
groups (Table 1). HUH is the only national center for solid organ trans-
plantations and also responsible for themajority of stem cell transplan-
tations nationally. This explains the quite high number of hematological
comorbidities in this study. Patients in the si-MALDI-TOF group had im-
munosuppressive medication more often than the ones in the control
group (63.8% versus 47.3%, P = 0.066). None of the patients had an
HIV infection. The most common source of bacteremia was abdominal
cavity (44.4%), with second being urinary tract (16.9%) (Table 1).
Seven-day mortality was 2.4% (n = 3) and 30-day mortality was
12.9% (n = 16), with no statistically signiﬁcant difference between
study groups (data not shown).
3.2. Microbiology and si-MALDI-TOF results
Pseudomonas aeruginosa caused 21 (16.9%) bacteremia episodes,
Enterococcus spp. 62 (50%), and AmpC-producing Enterobacteriaceae
41 (33.1%). These results are shown in more detail in Table 2. Of all
103 monobacteremias, si-MALDI-TOF was done in 65 and yielded a re-
sult in 62 (3 bacteremias without a result: 1 E. faecium, 2 E. cloacae). Of
polymicrobial bacteremias (n=21), si-MALDI-TOF was done in 14 and
yielded a result in 7 (for the index bacteria).
3.3. Early initiated empiric antibiotic treatment
In 75.8% (n=94) of bacteremia episodes caused by the index bacte-
ria, antibiotic treatment was either started or changed within 12 h afterPlease cite this article as:M. Halavaara, A. Nevalainen, T. Martelius, et al., Im
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to the ongoing inappropriate antibiotic treatment; and 6 patients re-
ceived no antibiotic treatment at all. Subsequently, early initiated em-
piric antibiotic treatment was appropriate only in 22.6% (n = 28) of
the bacteremia episodes in this study, and in the remaining episodes,
treatments were inappropriate.
3.4. Impact of si-MALDI-TOF analysis on antibiotic treatment
In 72.6% (n=90) of all bacteremia episodes, patients received appro-
priate antibiotic treatment within 48 h from the ﬁrst positive blood cul-
ture draw. In si-MALDI-TOF group, this percentage was 78.3% (n = 54)
and in control group 65.5% (n = 36); P = 0.112 by univariate analysis
(Table 3). A similar trend was seen in Kaplan–Meier survival analysis
(Fig. 1). However, in BSIs caused by Enterococcus spp. (n= 62), a signiﬁ-
cantly higher percentage of cases received appropriate antibiotic therapy
within 48 h in si-MALDI-TOF group (87.9% versus 65.5% in the control
group, P = 0.036). Results for different subgroups according to the
index bacteria are shown in Table 3.
A signiﬁcant beneﬁt of si-MALDI-TOF identiﬁcation was seen in the
treatment of bacteremic episodes in patients with immunosuppressive
medication (n = 70). In si-MALDI-TOF group, 86.4% (n = 38/44) and,
in control group, 57.7% (n = 15/26) cases had appropriate antibiotic
treatment within 48 h from blood culture draw (P= 0.007), as shown
in Fig. 2.
In general, median time from blood culture draw to receipt of appro-
priate antibiotic treatment was 33.5 h (interquartile range [IQR] 19.3–
49.5). In si-MALDI-TOF group versus control group, median times
were 31.9 h (IQR 14.9–46.8) and 39.7 h (IQR 21.2–61.4), respectively
(P= 0.230).
4. Discussion
In this study, we showed that enhanced MALDI-TOF analysis, si-
MALDI-TOF, was valuable in guiding the antibiotic treatment of bacter-
emia episodes caused by Pseudomonas aeruginosa, Enterococcus spp.,
and AmpC-producing Enterobacteriaceae. Si-MALDI-TOF increased the
proportion of appropriate antibiotic treatment within 48 h from the
blood culture draw by 12.8%. Signiﬁcant improvement in proportion of
patients with appropriate treatment was seen in Enterococcus spp.
group (22.4%, P= 0.036). Of all cases, the antibiotic treatment was ap-
propriate only in 22.6% of caseswithin 12 h from the blood culture draw
but was improved to 72.6% within 48 h. In patients with immunosup-
pressive medication, si-MALDI-TOF signiﬁcantly increased the percent-
age of cases receiving appropriate antibiotic treatmentwithin 48 h from
blood culture draw.
In a study by Vlek and colleagues, it was demonstrated that, in 218
patients with BSI, rapid MALDI-TOF was associated with an 11.3% in-
crease in the proportion of appropriate antibiotic treatment after 24 hpact of short-incubationMALDI-TOFMS on empiric antibiotic therapy
ious Disease, https://doi.org/10.1016/j.diagmicrobio.2018.11.009
Table 3
Number of bacteremia episodes (BE) on appropriate antibiotic treatment within 48 h from the ﬁrst positive blood culture draw.
Total number
n (%)
Si-MALDI-TOF group Control group P value
All bacteremia episodes in study group 90/124 (72.6) 54/69 (78.3) 36/55 (65.5) 0.112
BE caused by Pseudomonas aeruginosa 16/21 (76.2) 11/14 (78.6) 5/7 (71.4) N0.99
Enterococcus spp. 48/62 (77.4) 29/33 (87.9) 19/29 (65.5) 0.036
Amp-C producing Enterobactariaceae 26/41 (63.4) 14/22 (63.6) 12/19 (63.2) 0.975
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sult is in line with our study, although for Enterococcus spp., the impact
of si-MALDI-TOF was greater (65.5% vs. 87.9%), suggesting special ben-
eﬁt in that group.
In another study by Clerc et al. including 202 episodes of gram-
negative bacteremias, enhanced MALDI-TOF analysis had an impact on
empiric antibiotic therapy in 35.1% of bacteremia episodes and in
59.3% of the episodes caused by AmpC-producing Enterobacteriaceae
(n=27) (Clerc et al., 2013). Compared to our study, the number of bac-
teremias caused by the Enterobacter spp. and other AmpC-producing
Enterobacteriaceae was lower. In spite of the higher number of BSIs
caused by AmpC-producing Enterobacteriaceae, we could not detect
any difference between the study groups. One possible explanation is
that, in the study by Clerc et al., only patients for whom ID consultation
was performed were included.
In a recent study, the beneﬁt of rapid MALDI-TOF identiﬁcation was
evaluated in a setting with preexisting antimicrobial stewardship team
program(Osthoff et al., 2016). Although it did not have an impact on the
duration of intravenous antibiotic therapy, it led to lowered admission
frequency to the intensive care unit after BSI onset. The MALDI-TOF
analysis seemed to offer an extra beneﬁt in a subgroup that included
AmpC-producing Enterobacteriaceae and Enterococcus spp. In the 2
studies, additional beneﬁt of MALDI-TOF method was suggested inFig. 1. Kaplan–Meier survival analysis (log rank) b
Please cite this article as:M. Halavaara, A. Nevalainen, T. Martelius, et al., Im
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(Clerc et al., 2013; Osthoff et al., 2016).
In the recent study by Jeon et al., the use of MALDI-TOF alone did not
signiﬁcantly reduce the time to effective therapy (Jeon et al., 2018). This
is in contrast to our study, which adds to the body of evidence on ben-
eﬁts of si-MALDI-TOF on antibiotic treatment of patients with BSIs
caused by the index bacteria in our study. However, further studies
will be needed, as noted in a recent meta-analysis, which also empha-
sized that earlier information should also lead to an appropriate clinical
response (Dixon et al., 2015). This idea is further supported in a recent
study on 239 BSI patients showing that MALDI-TOF method combined
with antimicrobial stewardship intervention was more powerful than
MALDI-TOF MS alone (Beganovic et al., 2017).
An interestingﬁnding is the impact of si-MALDI-TOF in a subgroupof
patients with immunosuppressive medication. In this group of patients,
the proportion on appropriate antibiotic treatmentwithin 48 h from the
blood culture draw was signiﬁcantly larger in the si-MALDI-TOF group
than in the control group. This ﬁnding is difﬁcult to explain. Looking
only at bacteremic episodes in patients with immunosuppressive med-
ication with inappropriate initial empiric antibiotic therapy, the differ-
ence remains (n = 54, 81.8% vs. 46.7%, P= 0.008). The proportions of
different bacteria are also the same (e.g., Enterococcus spp. 52.9%, rest
of the data not shown). One possible explanation is that the treatingetween the 2 study groups, censored at 48 h.
pact of short-incubationMALDI-TOFMS on empiric antibiotic therapy
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advantage of the information provided by the rapid diagnostics.
In clinical work, the antibiotic treatment is usually initiated after
blood culture draw; in this study in 75.8% of cases. However, the antibi-
otic treatment was appropriate only in 22.6% of bacteremic episodes
within 12 h after the blood culture draw. Empiric antibiotic therapy is
often not changed until further microbial or clinical evidence is ob-
tained, which usually takes at least 48 h. This highlights the importance
of methods like si-MALDI-TOF that speed up the identiﬁcation of bacte-
ria in patients with BSI. Indeed, in clinical routine, information acquired
from short-incubation MALDI-TOF method led to a change in empiric
antibiotic treatment in 20% of patients with bacteremia (179 antibiotic
prescriptions analyzed), and three quarters of these changes were con-
sidered rational by the authors (Kock et al., 2017).
Themost plausible explanation why si-MALDI-TOF analysis brought
a statistically signiﬁcant beneﬁt particularly in enterococcal bacter-
emias is the natural resistance proﬁle of these microbes. Antibiotics ef-
fective also against enterococci are seldom included in empiric (in HUH
often second- or third-generation cephalosporin) as well as in second-
line antibiotic treatment (often a more broad spectrum beta-lactam).
This is especially highlighted in BSI caused by E. faecium, which is
often resistant to beta-lactams and requires vancomycin implemented
in the regimen. Indeed, in 83.9% (n = 52) of all enterococcal bacter-
emias, the early empiric therapy was inappropriate. An effective cover-
age was obtained by expanding the regimenwith either vancomycin or
linezolid (67.3%, n = 35) or, alternatively, with enterococcal beta-
lactam (32.7%, n= 17). This was seen clearly in E. faecium bacteremias
(n= 37) where vancomycin was needed in 86.5% (n= 32) of cases in
order to make the antibiotic therapy effective.
The strength of this study is its focus on the group of bacteria requir-
ing special attention towards antibiotic therapy. Another strength is
that the impact of si-MALDI-TOF information on antibiotic treatment
could be evaluated independently of antimicrobial stewardship team
since it was introduced to a routine clinical setting (i.e., real-world
data). Although this is a single-center study, patient population was
quite wide and diverse. Advantage of a single-center study is that all
samples were analyzed in a single microbial university laboratory
(HUSLAB).
There are several limitations in our study. It is a single-center study
and is retrospective. Bacteremia episodes were divided into 2 study
groups as described above, so presence of confounding factors is possi-
ble. If si-MALDI-TOF did not recognize the index bacteria from positive
blood culture, clinicians did not receive any microbial information ear-
lier, and hence, these bacteremia episodes were placed in the controlPlease cite this article as:M. Halavaara, A. Nevalainen, T. Martelius, et al., Im
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was not evaluated. Importantly, quite a high number of patients had
neutropenia or were otherwise immunosuppressed, and in many
cases, the source of infection was the abdominal cavity. These are situa-
tions where de-escalation is often not plausible even when bacteria in
blood are recognized. In addition, the natural resistance proﬁle of the
bacteria in our study often necessitates the use of broad-spectrum anti-
biotics. In polymicrobial infections, the appropriateness of antibiotic
therapy was assessed from the perspective of the index bacteria. How-
ever, in every polymicrobial bacteremia episode, appropriateness of an-
tibiotic therapy was reached when index bacteria were covered. Si-
MALDI-TOF provides faster recognition to species level but no further
information about antimicrobial susceptibility of the bacteria. Thus,
our ﬁndings might not be generalizable to a setting where prevalence
of more resistant bacteria (e.g., VRE, MDR Pseudomonas) is higher. The
number of cases was too low to properly assess this method's impact
on mortality. However, as noted in a recent meta-analysis, true mortal-
ity beneﬁtsmay be difﬁcult to detectwhen assessing the beneﬁts ofmo-
lecular rapid detection test, and time to appropriate antibiotic therapy is
a better indicator (Timbrook et al., 2017).
5. Conclusion
Si-MALDI-TOF is a useful tool in the treatment of patients with
bloodstream infections. It increases the number of patients receiving
appropriate antibiotic treatment within 48 h from blood culture draw.
A statistically signiﬁcant impact was observed in patients with BSI
caused by Enterococcus spp. and in a subgroupof patientswith immuno-
suppressive medication.
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